“In 2014, President Xi Jinping said that the localization of medical equipment is imperative, and that the localization of high-end medical equipment must be accelerated to promote the continuous development of local enterprises through technological innovation and cost reduction.In 2015, the promulgation of “Made in China 2025″ also included domestically produced high-end medical equipment in its strategic tasks and priorities, and made every effort to promote the localization of medical equipment to accelerate the development.” said Cheng Gong, senior engineer of Shenzhen RayMing Technology.
Driven by the policy dividends continuously released by the state, the domestic medical equipment manufacturers to complete the import substitution has also turned into the year of attack. 2016, the three multinational medical equipment giants are still the biggest competitors. And the state encourages the localization of medical devices is the inevitable choice of the wave of import substitution.
For the first time, the three medical device international giants GPS (GE, Philips, Siemens) collectively absent from the 76th CMEF (China International Medical Equipment Autumn Fair), which caused quite a stir in the circle.
However, there are pros and cons in the development of things. If Meizu, Lianyin, Neusoft is now the epitome of the 300 billion domestic medical device market, in the multinational enterprises momentum fierce “localization” strategy, this alternative war is not so good to go. The road of localization still has a long way to go, to compete with GPS head-on, it will be very difficult, need some differentiation to pursue a specific market share.
CMEF as an industry event, GPS collective absence is not a small thing. The reporter visited the 76th CMEF some time ago, found that the exhibitors to the United Imaging, Myriad, Neusoft-based domestic medical device head as the main force to replace the three giants. rayMing Technology’s Cheng Gong analysis said, “This means that the domestic high-end medical device products are emerging, the tide of import substitution really came.”
Since its establishment, Shenzhen RayMing Technology has long focused on the reverse technology research of high-end medical devices as well as secondary development, providing full life-cycle technology solutions for a wide range of small and medium-sized customers. Driven by the frequent release of national policy dividends, RayMing Technology will accelerate the research and development of high-end medical equipment and play a role in the localization of high-end digital diagnosis and treatment equipment.
